Myra E. van Linde
Impact in
- Genetics top 2%
- Glioma Diagnosis and Treatment
-
- Cancer, Hypoxia, and Metabolism
Papers in
- Co-authors
- Wouter R. van Furth (3 shared papers)Lukas J.A. Stalpers (3 shared papers)Joost J.C. Verhoeff (3 shared papers)D. J. Richel (3 shared papers)Henk M.W. Verheul (18 shared papers)Jaap C. Reijneveld (6 shared papers)Annemiek Walenkamp (8 shared papers)Roelien H. Enting (7 shared papers)
- Journals
- Annals of Oncology (3 papers)Journal of Clinical Oncology (3 papers)Neuro-Oncology (3 papers)The Oncologist (2 papers)Neuro-Oncology Advances (2 papers)
- Partner nations
- NetherlandsUnited StatesSpain
In The Last Decade
Myra E. van Linde
31 papers receiving 750 citations
Peers
Comparison fields: 5 of 77
- Genetics 340
- Cancer Research 132
- Oncology 163
- Pulmonary and Respiratory Medicine 105
- Immunology 66
Countries citing papers authored by Myra E. van Linde
This map shows the geographic impact of Myra E. van Linde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Myra E. van Linde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Myra E. van Linde more than expected).
Fields of papers citing papers by Myra E. van Linde
This network shows the impact of papers produced by Myra E. van Linde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Myra E. van Linde. The network helps show where Myra E. van Linde may publish in the future.
Co-authors
The 25 scholars most cited alongside Myra E. van Linde, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 154 | |
| 2 | 2017 | 149 | |
| 3 | 2010 | 76 | |
| 4 | 2017 | 73 | |
| 5 | 2020 | 48 | |
| 6 | 2014 | 29 | |
| 7 | 2021 | 25 | |
| 8 | 2020 | 22 | |
| 9 | 2019 | 21 | |
| 10 | 2015 | 20 | |
| 11 | 2022 | 18 | |
| 12 | 2021 | 16 | |
| 13 | 2016 | 15 | |
| 14 | 2015 | 15 | |
| 15 | 2020 | 13 | |
| 16 | 2019 | 11 | |
| 17 | 2019 | 10 | |
| 18 | 2022 | 7 | |
| 19 | 2024 | 7 | |
| 20 | 2020 | 5 |
About Myra E. van Linde
Myra E. van Linde is a scholar working on Genetics, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology, having authored 36 papers that have together received 772 indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (17 papers), Cancer survivorship and care (5 papers), Cancer, Hypoxia, and Metabolism (4 papers), Brain Metastases and Treatment (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), CAR-T cell therapy research (2 papers), Nanoplatforms for cancer theranostics (1 paper) and Ferroptosis and cancer prognosis (1 paper). The work is most often cited by research in Genetics (340 citations), Cancer Research (132 citations), Oncology (163 citations), Pulmonary and Respiratory Medicine (105 citations) and Immunology (66 citations). Myra E. van Linde has collaborated with scholars based in Netherlands, United States and Spain. Frequent co-authors include Wouter R. van Furth, Lukas J.A. Stalpers, Joost J.C. Verhoeff, D. J. Richel, Henk M.W. Verheul, Jaap C. Reijneveld, Annemiek Walenkamp, Roelien H. Enting, William P. J. Leenders and An Claes. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Neuro-Oncology, The Oncologist and Neuro-Oncology Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.